Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Renal cell carcinoma and the use of sorafenib

Authors James MG Larkin, Tim Eisen

Published 15 March 2006 Volume 2006:2(1) Pages 87—98

James MG Larkin, Tim Eisen

Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK

Abstract: Immunotherapy results in a small overall survival advantage in metastatic renal cell carcinoma (RCC), but there is a need to develop more effective systemic therapies. Angiogenesis has an important role in the pathophysiology of RCC and vascular endothelial growth factor (VEGF) is a key mediator of this process. Sorafenib (BAY 43-9006) is a new agent belonging to a class of drugs called kinase inhibitors and inhibits the VEGF, platelet-derived growth factor (PDGF), and c-KIT receptor tyrosine kinases, amongst others. Sorafenib has shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies in patients pretreated with immunotherapy, whilst prolonged progression-free survival in comparison with placebo in a phase 3 study has been reported. Further phase 3 trials in advanced disease are ongoing and a trial of adjuvant sorafenib therapy in RCC is planned.

 

Keywords: Renal cell carcinoma; metastatic; systemic therapy; sorafenib

Download Article [PDF] 

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Aneuploidogenic effects and DNA oxidation induced in vitro by differently sized gold nanoparticles

Di Bucchianico S, Fabbrizi MR, Cirillo S, Uboldi C, Gilliland D, Valsami-Jones E, Migliore L

International Journal of Nanomedicine 2014, 9:2191-2204

Published Date: 8 May 2014

Past, present, and future of hormonal therapy in recurrent endometrial cancer

Carlson MJ, Thiel KW, Leslie KK

International Journal of Women's Health 2014, 6:429-435

Published Date: 2 May 2014

A case of mitochondrial cardiomyopathy with restrictive transmitral filling pattern

Otsui K, Inoue N, Tamagawa A, Onishi K

International Medical Case Reports Journal 2012, 5:19-22

Published Date: 13 April 2012

Effects of treatment with antimicrobial agents on the human colonic microflora

Fatemeh Rafii, John B Sutherland, Carl E Cerniglia

Therapeutics and Clinical Risk Management 2008, 4:1343-1357

Published Date: 5 December 2008

Venlafaxine extended release (XR) in the treatment of panic disorder

Kevin Kjernisted, Diane McIntosh

Therapeutics and Clinical Risk Management 2007, 3:59-69

Published Date: 15 March 2007